- Home
- LEGH vs MLYS Comparison
LEGH vs MLYS Comparison
Compare LEGH & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEGH
- MLYS
- Stock Information
- Founded
- LEGH 2005
- MLYS 2019
- Country
- LEGH United States
- MLYS United States
- Employees
- LEGH N/A
- MLYS N/A
- Industry
- LEGH Homebuilding
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- LEGH Consumer Discretionary
- MLYS Health Care
- Exchange
- LEGH Nasdaq
- MLYS Nasdaq
- Market Cap
- LEGH 588.8M
- MLYS 1.0B
- IPO Year
- LEGH 2018
- MLYS 2023
- Fundamental
- Price
- LEGH $23.04
- MLYS $14.63
- Analyst Decision
- LEGH Strong Buy
- MLYS Strong Buy
- Analyst Count
- LEGH 2
- MLYS 4
- Target Price
- LEGH $29.00
- MLYS $27.00
- AVG Volume (30 Days)
- LEGH 100.7K
- MLYS 885.1K
- Earning Date
- LEGH 08-07-2025
- MLYS 08-12-2025
- Dividend Yield
- LEGH N/A
- MLYS N/A
- EPS Growth
- LEGH 8.04
- MLYS N/A
- EPS
- LEGH 2.29
- MLYS N/A
- Revenue
- LEGH $176,618,000.00
- MLYS N/A
- Revenue This Year
- LEGH N/A
- MLYS N/A
- Revenue Next Year
- LEGH $8.23
- MLYS N/A
- P/E Ratio
- LEGH $10.04
- MLYS N/A
- Revenue Growth
- LEGH N/A
- MLYS N/A
- 52 Week Low
- LEGH $21.58
- MLYS $8.24
- 52 Week High
- LEGH $29.31
- MLYS $18.38
- Technical
- Relative Strength Index (RSI)
- LEGH 53.84
- MLYS 54.08
- Support Level
- LEGH $23.25
- MLYS $14.07
- Resistance Level
- LEGH $24.20
- MLYS $14.70
- Average True Range (ATR)
- LEGH 0.65
- MLYS 0.69
- MACD
- LEGH 0.07
- MLYS 0.15
- Stochastic Oscillator
- LEGH 62.17
- MLYS 80.69
About LEGH Legacy Housing Corporation (TX)
Legacy Housing Corp builds, sell, and finance manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores and also sold directly to manufactured home communities. The company also provides financing options to its customers to facilitate the sale of homes.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.